\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Horizon Europe SwafSA call for applications for the European Group on Ethics in Science and New Technologies (EGE) was launched by the European Commission. The EGE is an independent advisory body which was founded in 1991 and reports to the President of the European Commission and the College of Commissioners and acts under the direct responsibility of the European Commissioner for Innovation, Research, Culture, Education and Youth. Recent advice was provided on the following topics: the protection of fundamental rights in the COVID-19 pandemic, genome editing and artificial intelligence. The expert group will consist of up to 15 members. Members are appointed for a term of maximum 3 years which can be renewed a maximum of two times.
Applications should include a cover letter, curriculum vitae and standard declaration of interest and will have to be submitted via this website. The deadline for applications is 22 March 2021 (12:00 noon CET). Questions related to the application process can be addressed to EC-ETHICS-GROUP@ec.europa.eu.
All information related to the call can be found in this European Commission news article
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
